Invesco Ltd. grew its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 679.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 247,086 shares of the company's stock after purchasing an additional 215,375 shares during the period. Invesco Ltd. owned approximately 0.35% of Altimmune worth $1,781,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new stake in Altimmune in the fourth quarter worth $45,000. Cullen Frost Bankers Inc. purchased a new position in Altimmune during the 4th quarter valued at $72,000. 180 Wealth Advisors LLC bought a new position in Altimmune in the 4th quarter valued at $78,000. KLP Kapitalforvaltning AS purchased a new stake in Altimmune in the fourth quarter worth $81,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Altimmune during the fourth quarter valued at $88,000. Institutional investors own 78.05% of the company's stock.
Insider Activity
In other news, CFO Gregory L. Weaver purchased 10,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares of the company's stock, valued at $52,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 4.10% of the company's stock.
Altimmune Stock Performance
NASDAQ:ALT traded down $0.20 during midday trading on Monday, reaching $5.57. 472,970 shares of the stock traded hands, compared to its average volume of 2,848,397. The stock has a market capitalization of $429.28 million, a PE ratio of -3.60 and a beta of 1.13. Altimmune, Inc. has a 12-month low of $3.55 and a 12-month high of $11.16. The business has a 50-day moving average of $5.16 and a two-hundred day moving average of $6.65.
Altimmune (NASDAQ:ALT - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.01. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. Research analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on ALT shares. HC Wainwright restated a "buy" rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, April 3rd. Stifel Nicolaus initiated coverage on Altimmune in a research note on Wednesday, January 8th. They set a "buy" rating and a $18.00 price target on the stock. Finally, William Blair reissued a "market perform" rating on shares of Altimmune in a research report on Friday, March 14th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $20.83.
View Our Latest Research Report on Altimmune
Altimmune Company Profile
(
Free Report)
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
See Also

Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.